Payment overview · 2025
General Payments
$514.21
34 reported records · 7 companies
Healthcare provider profile · identity verified
Kenneth Bain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAWRENCEBURG, KY · NPI 1063470714
Verified facts
What the public records show
CMS Open Payments records show Kenneth Bain, MD received $514.21 in general payments during 2025 across 34 reported records.
GlaxoSmithKline, LLC. accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $191.67 | 37.3% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.73 | 36.5% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.36 | 7.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.19 | 7.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.45 | 4.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.95 | 3.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.86 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $514.21 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $191.67 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $104.99 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.28 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.40 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 237 |
| Omeprazole | Omeprazole | 455 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 416 | 116 |
| Lisinopril | Lisinopril | 368 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 107 |
| Metformin Hcl | Metformin Hcl | 276 | 82 |
| Gabapentin | Gabapentin | 256 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 253 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 76 |
| Losartan Potassium | Losartan Potassium | 179 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 55 |
| Carvedilol | Carvedilol | 156 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 51 |
| Metformin Hcl Er | Metformin Hcl | 140 | 47 |
| Trazodone Hcl | Trazodone Hcl | 139 | 47 |
| Furosemide | Furosemide | 125 | 47 |
| Allopurinol | Allopurinol | 119 | 32 |
| Potassium Chloride | Potassium Chloride | 113 | 35 |
| Sertraline Hcl | Sertraline Hcl | 108 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 30 |
| Tramadol Hcl | Tramadol Hcl | 106 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 59 |
| Alprazolam | Alprazolam | 92 | 16 |
| Famotidine | Famotidine | 91 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 27 |
| Simvastatin | Simvastatin | 85 | 25 |
| Finasteride | Finasteride | 84 | 24 |
| Montelukast Sodium | Montelukast Sodium | 82 | 24 |
| Ozempic | Semaglutide | 82 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 75 | 20 |
| Prednisone | Prednisone | 73 | 59 |
| Buspirone Hcl | Buspirone Hcl | 72 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 22 |
| Bupropion Xl | Bupropion Hcl | 67 | 19 |
| Glimepiride | Glimepiride | 66 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 21 |
| Ezetimibe | Ezetimibe | 65 | 21 |
| Eliquis | Apixaban | 64 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 18 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 17 |
| Azithromycin | Azithromycin | 54 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 16 |
| Spironolactone | Spironolactone | 50 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 15 |
| Trulicity | Dulaglutide | 44 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 40 |
| Glipizide | Glipizide | 41 | 12 |
| Valsartan | Valsartan | 41 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 15 |
| Meloxicam | Meloxicam | 39 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 24 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Torsemide | Torsemide | 36 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 15 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Nystatin | Nystatin | 30 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 20 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 15 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 18 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $514.21 · 34 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error